The past 20 years has seen transdermal technology become an accepted method of delivering medicines as they can offer significant clinical benefits over other dosage forms.


Syntropharma development activities are focused on the repositioning/ reformulation of existing approved drugs.

Management Team and Board of Directors

The Syntropharma Board have many years experience of the Life Science sector.

Our collective mission is to create new treatment options for the large number of people with unmet medical needs in the Psychiatric and Central Nervous System space.

Enthusiasm, drive and commitment have been key attributes in the Companies development.

Andrew Gardiner

Founder & CEO

Ian Scott

Non-Executive Director

Stephane Méry

Non-Executive Director